| 标题 |
Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer |
| 网址 | |
| DOI |
10.1093/oncolo/oyaf148
doi
|
| 其它 |
期刊:The Oncologist 作者:Lorenzo Antonuzzo; Hidenori Takahashi; Joon Oh Park; Aumkhae Sookprasert; Roopinder Gillmore; et al 出版日期:2025-07-01 |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)